Why the study?
RHD remains a major cause of preventable morbidity in low- and middle-income countries, and clarity was needed on the systemic immune signatures associated with valvular pathology.
Does the assessment of systemic and cellular immune response biomarkers identify immunological alterations associated with disease severity and progression in patients with acute rheumatic fever or rheumatic heart disease?
Does the assessment of systemic and cellular immune response biomarkers identify immunological alterations associated with disease severity and progression in patients with acute rheumatic fever or rheumatic heart disease?
Answers are grounded in this paper and cite their sources.
This systematic review demonstrates that systemic immune dysregulation in acute rheumatic fever and rheumatic heart disease mirrors local valvular inflammation and fibrosis, highlighting specific T-cell subsets and cytokines (such as IL-6, TNF-α, IL-17, TGF-β1, and ProTα) as candidate biomarkers for disease severity and potential therapeutic targets.
Rheumatic heart disease (RHD) remains a major cause of preventable morbidity in low- and middle-income countries. As the most serious sequel of acute rheumatic fever (ARF) caused by Streptococcus pyogenes, RHD arises from molecular mimicry that drives autoimmune damage of cardiac valves. We systematically reviewed human studies (1977–2025) following PRISMA to clarify systemic immune signatures associated with valvular pathology. Searches of PubMed, LILACS, ScienceDirect, and Web of Science found 29 studies: 22 RHD and 7 ARF. In ARF, elevations in IL-6, IL-8, IL-17F, GM-CSF, TNF-a, and CXCL10 occurred alongside increased activity of CD4+ Th1 and MAIT cells. In RHD, a consistent inflammatory–fibrotic profile emerged with raised IL-17, IFN-γ, TNF-a, TGF-β1, Tenascin-C, and prothymosin alpha (ProTα) in blood and valve tissue. CD4+ and CD8+ T cells were implicated in valve injury; ProTα correlated with cytotoxic activity of circulating CD8+ T cells. Several mediators (IL-6, TNF-a, IL-8, CXCL10, CCL2, CCL19) were identified in RHD studies as being associated with inflammation, cell recruitment, and clinical severity. Systemic dysregulation mirrored local valve inflammation, suggesting circulating molecules may index ongoing cardiac damage. These findings underscore a central role for T cells and pro-inflammatory cytokines in RHD and highlight candidate prognostic markers and therapeutic targets to inform translational studies and trials.
No takes yet. Share an insight, caveat, or question.
Neves et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: